An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 561-568

  Liu, Dongfang ^a   Bachmann, Kenneth A ^a,b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRADIOL; CHOLESTEROL; ESTRADIOL; ESTROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; FEMALE; HYPOCHOLESTEROLEMIA; HYPOLIPEMIA; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; CHOLESTEROL; ESTRADIOL; FEMALE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; UTERUS;

EID: 0031847271     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Aftergood L, Hernandez HJ and Alfin-Slater RB (1968) Effect of large of doses of the oral contraceptive enovid on cholesterol metabolism in the rat. J Lipid Res 9:447-451.
2. Arts J, Kuiper GG, Janssen JM, Gustafsson, J-Å, Lowik CW, Pols HA and Van Leeuwen JP (1997) Differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138: 5067-5070.
3. Ball P, Gunter E, Kayser H and Teichmann J (1983) Metabolic clearance rates of catechol estrogens in rats. Endocrinology 113:1781-1783.
4. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD and Bryant HU (1994) Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 83:63-69.
5. Bolt HM (1981) Metabolism of estrogens: Natural and synthetic. In: International Encyclopedia of Pharmacology & Therapeutics, Section 106 (Chaudry RR ed) pp. 19-39, Pergamon Press, New York.
6. Campos H, Wilson P, Jimenez D, McNamara JR, Ordovsas J and Schaefer EJ (1990) Differences in apolipoprotein and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: Results from the Framingham Offspring Study. Metabolism 39:1033-1038.
7. Chao YS, Windier EE, Chen GC and Havel RJ (1979) Hepatic catabolism of rat and human lipoproteins in rats treated with 17α-ethinyl estradiol. J Biol Chem 254: 11360-11366.
8. Cooper AD, Nutik R and Chen J (1987) Characterization of the estrogen-induced lipoprotein receptor of rat liver. J Lipid Res 28:59-68.
9. Cypriani B, Tabacik C, Descomps B and Crastes de paulet A (1988) Role of estrogen receptors and antiestrogen binding sites in an early effect of antiestrogens, the inhibition of cholesterol biosynthesis. J Steroid Biochem 31:763-771.
10. Davies IJ, Naftolin F, Ryan KJ, Fishman J and Siu J (1975) The affinity of catechol estrogens for estrogen receptors in the pituitary and anterior hypothalamus of the rat. Endocrinology 97:554-557.
11. Davis RA and Roheim PS (1978) Pharmacologically induced hypolipidemia. Atherosclerosis 30:293-299.
12. Emons G, Gruhn-Schultek KM, Isedor S, Ball P and Knuppen R (1982) Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates. Steroid 39:291-299.
13. Fewster ME, Pirrie RE and Turner DA (1967) Effect of estradiol benzoate on lipid metabolism in the rat. Endocrinology 80:263-266.
14. Fishman J and Martucci C (1980) Biological properties of 16 α-hydroxyestrone implications in estrogen physiology and pathophysiology. J Clin Endocr Metab 51:611-615.
15. Frolik CA, Bryant HU, Black EC, Magge DE and Chandrasekhar S (1996) Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCL, tamoxifen, estrogen, and alendronate. Bone 18:621-627.
16. Grady D, Rubin SM, petitti DB, Fox CS, Black D, Ettinger B, Ernster VL and Cummings SR (1992) Hormone therapy to prevent disease to prolong life in postmenopausal women. Ann Intern Med 117:1016-1037.
17. Henderson BE, Ross RK and Pike MC (1993) Hormonal chemoprevention of cancer in women. Science 259:633-638.
18. Jellinck PH, Krey L, Davis PG, Kamel F, Luine V, Parsons B, Roy EJ and Mcewen BS (1981) Central and peripheral action of estradiol and catecholestrogens administered at low concentration by constant infusion. Endocrinology 108: 1848-1854.
19. Josefsson E and Tarkowski A (1997) Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 40:154-163.
20. Judd HL, Meldrum DR, Deftos LJ and Henderson BE (1983) Estrogen replacement therapy: Indications and complications. Ann Intern Med 98:195-205.
21. Klauber N, Parangi S, Flynn E, Hamel E and D'Amato J (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 57:81-86.
22. Klinge CM, Traish AM, Bambara RA and Hilf R (1996) Dissociation of 4-hydroxytamoxifen, but not estradiol or tamoxifen aziridine, from the estrogen receptor as the receptor binds estrogen response element DNA. J Steroid Biochem Mol Biol 57:51-66.
23. Kovanen PT, Goldstein JL and Brown MS (1978) Increased binding of low density lipoproteins to liver membranes from rats treated with 17-α-ethinyl estradiol. J Biol Chem 254:11367-11373.
24. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S and Gustafsson J-Å (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930.
25. Lazier CB and Bapat BV (1988) Antiestrogen binding sites: General and comparative properties. J Steroid Biochem 31:665-669.
26. Levin W, Welch RM and Conney AH (1968) Effect of phenobarbital and other drugs on the metabolism and uterotropic action of estradiol-17β and estrone. J Pharmacol Exp Ther 150:371.
27. Levin W, Welch RM and Conney AH (1967) Effect of chronic phenobarbital treatment on the liver microsomal metabolism and uterotropic action of 17β-estradiol. Endocrinology 80:135-140.
28. Martucci C and Fishman J (1977) Direction of estradiol metabolism as a control of its hormonal action: Uterotropic activity of estradiol metabolites. Endocrinology 101: 1709-1715.
29. Martucci C and Fishman J (1976) Uterine estrogen receptor binding of catecholestrogens and esterol. Steroid 27:325-333.
30. Martucci C and Fishman J (1979) Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology 105:1288-1292.
31. Martucci CP and Fishman J (1993) P450 enzymes of estrogen metabolism. Pharmacol Ther 57:237-257.
32. McDonnell DP, Clemm DL, Hermann T, Goldman ME and Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669.
33. Merrian GR, Maclusky NJ, Picard MK and Naftolin F (1980) Comparative properties of the catechol estrogens. I: Methylation by catechol-O methyltransferase and binding to cytosol estrogen receptors. Steroid 36:1-11.
34. Mosselman S, Polman J and Dijkema R (1996) ERβ: Identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53.
35. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR and DeGregorio MW (1992) Tamoxifen and the isomers of 4-hydroxytamoxifen in the tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10:304-310.
36. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson, J-Å, Kushner PJ and Scanlan TS (1997) Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508-1510.
37. Robinson RW, Higanov N and Cohen WD (1959) Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch Intern Med 104:908-913.
38. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ and Speizer FE (1981) Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 139:47-51.
39. Schutze N, Tiemann V, Geiger M and Knuppen R (1993) Catecholestrogens are MCF-7 cell estrogen receptor agonists. J Steroid Biochem Mol Biol 46:781-789.
40. Srivastavs TA, Baumann D and Schonfeld G (1993) In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse. Eur J Biochem 216:527-538.
41. Suchar LA, Chang RL, Thomas PE, Rosen RT, Lech J and Conney AH (1996) Effects of phenobarbital, dexamethasone, and 3-methylcholanthrene administration on the metabolism of 17-β-estradiol by liver microsomes from female rats. Endocrinology 137:663-676.
42. Tanaka T, Katoh M and Kubodera A (1986) The characteristic binding of catecholestrogens to estrogen receptors in 7,12-dimethylbena[a]anthracene-induced rat mammary tumors. Steroid 48:361-368.
43. Telang TN, Katdare M, Bradlow HL and Osborne PM (1997) Estradiol metabolism: An endocrine biomarker for modulation of human mammary carcinogenesis. Environmental Health Perspec 105:559-564.
44. Teo CC, Kon OL, Sim KY and Ng SC (1992) Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as seletive ligands for antiestrogen-binding sites: Effects on cell proliferation and cholesterol synthesis. J Med Chem 35:1330-1339.
45. Wallace RB, Hoover J, Barrett-Lonnor E, et al (1979) Altered plasma lipid and lipoprotein levels associated with oral contraceptive and estrogen use. Lancet 2:111-114.
46. Waynforth HB and Flecknell PA (1992) Experimental and Surgical Technique in the Rat. Second Edition. Academic Press, pp. 276-278.